Want to see OCUL full AI Analyst Report?
Top Page
Ocular Therapeutix
(NASDAQ:OCUL)
Select Model
Select Model
Rating:55Neutral
Price Target:
$12.00
▲(10.29% Upside)
Action:Reiterated
Date:08/20/26
The score is primarily weighed down by weak financial performance—worsening losses and ongoing heavy cash burn despite strong gross margins and improved leverage. Technicals are supportive with clear strength versus moving averages, but overbought signals temper the near-term outlook. Valuation remains challenging due to negative earnings, and the recent equity plan expansion adds dilution risk.
Positive Factors
Strong Gross Margins
Consistently high-80% to low-90% gross margins indicate attractive product-level economics. This provides a durable foundation for scaling DEXTENZA and future products, although operating expenses and development spending have so far prevented profitability.
Negative Factors
Weak Revenue Traction
Revenue has not yet demonstrated durable acceleration: annual sales declined materially and trailing-twelve-month growth remains modest. Limited top-line expansion constrains operating leverage and reduces the company’s ability to absorb substantial fixed costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Gross Margins
Consistently high-80% to low-90% gross margins indicate attractive product-level economics. This provides a durable foundation for scaling DEXTENZA and future products, although operating expenses and development spending have so far prevented profitability.
Read all positive factors
Ocular Therapeutix (OCUL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.39B
Dividend YieldN/A
Average Volume (3M)2.70M
Price to Earnings (P/E)―
Beta (1Y)1.42
Revenue Growth-8.14%
EPS Growth-10.60%
CountryUS
Employees325
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.42
Shares Outstanding219,615,880
10 Day Avg. Volume1,771,105
30 Day Avg. Volume2,702,734
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)3.47
Price to Sales (P/S)43.86
P/FCF Ratio-10.48
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.78Price Target Upside136.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.5
Revenue Forecast (FY)$52.87M
Ocular Therapeutix Business Overview & Revenue Model
Company Description
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a ran...
How the Company Makes Money
Ocular Therapeutix primarily makes money through product revenue from sales of DEXTENZA in the U.S. The company recognizes revenue based on shipments/dispensing of DEXTENZA to customers (e.g., specialty distributors and/or healthcare providers, de...
Ocular Therapeutix Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 09, 2026
Earnings Call Sentiment Positive
The call conveyed a strongly positive clinical narrative: a landmark superiority result (p=0.0006), clear durability and anatomic benefits, an encouraging safety profile, robust enrollment and accelerated timelines for SOL-R, initiation of a long-term extension (SOL-X), and a solid cash position. The primary negatives were regulatory/timing uncertainty, the explicit note that cash runway excludes full commercialization costs, and limited disclosure of some granular metrics. On balance, the highlights substantially outweigh the lowlights.Positive Updates
First-in-Class Superiority in Phase III (SOL-1)
AXPAXLI (SOL-1) demonstrated statistical superiority versus an approved anti-VEGF in wet AMD with a primary endpoint p-value of 0.0006, marking the first novel investigational therapy to achieve this in a Phase III wet AMD trial.
Negative Updates
Regulatory and Timing Uncertainty
Although management reports productive, formal discussions with the FDA, specific meeting details and exact filing/timeline commitments were not disclosed; reliance on a single‑trial submission remains subject to ongoing FDA dialogue and potential changes in agency expectations.
Read all updates
Q1-2026 Updates
Positive
Negative
First-in-Class Superiority in Phase III (SOL-1)
AXPAXLI (SOL-1) demonstrated statistical superiority versus an approved anti-VEGF in wet AMD with a primary endpoint p-value of 0.0006, marking the first novel investigational therapy to achieve this in a Phase III wet AMD trial.
Read all positive updates
Company Guidance
Management guided that it remains on track to pursue an NDA relying on SOL‑1 week‑52 data (primary endpoint p=0.0006), leveraging a 505(b)(2) pathway and an existing SPA while continuing formal discussions with the FDA; SOL‑R completed randomization at 631 subjects (vs a 555 target) in Dec 2025 with top‑line data accelerated to Q1 2027, and SOL‑X has been initiated to give patients who complete 2 years in SOL‑1/SOL‑R an additional 3 years of AXPAXLI for a total of 5 years of follow‑up. They emphasized SOL‑1 efficacy and durability metrics — ~75% rescue‑free at ~9 months, ~66% maintaining vision through 12 months, ~56% maintaining CST within 30 microns after a single injection, ~5–6 months delayed time to >30/75 µm fluid increases versus aflibercept, and a 6‑month delay in reaching the aflibercept rescue rate (week 28 vs week 52) — plus a reassuring safety profile with no treatment‑related serious ocular/systemic AEs reported, and a strong financial position with approximately $667M cash as of March 31, 2026, providing runway into 2028 (excluding full commercialization spend); an Investor Day is scheduled for June 17, 2026.Ocular Therapeutix Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 52.05M | 51.82M | 63.72M | 58.44M | 51.49M | 43.52M |
| Gross Profit | 45.35M | 45.25M | 58.10M | 53.16M | 46.95M | 39.12M |
| EBITDA | -284.59M | -249.78M | -176.14M | -66.42M | -61.91M | 2.54M |
| Net Income | -301.45M | -265.94M | -193.51M | -80.74M | -71.04M | -6.55M |
Balance Sheet | ||||||
| Total Assets | 671.32M | 808.06M | 457.94M | 252.06M | 149.29M | 204.89M |
| Cash, Cash Equivalents and Short-Term Investments | 598.64M | 737.06M | 392.10M | 195.81M | 102.30M | 164.16M |
| Total Debt | 79.38M | 79.78M | 75.78M | 83.39M | 64.28M | 58.98M |
| Total Liabilities | 151.28M | 153.75M | 142.59M | 160.93M | 113.91M | 116.89M |
| Stockholders Equity | 520.04M | 654.31M | 315.34M | 91.13M | 35.38M | 88.00M |
Cash Flow | ||||||
| Free Cash Flow | -255.10M | -216.89M | -135.97M | -76.32M | -63.32M | -66.74M |
| Operating Cash Flow | -238.24M | -204.88M | -134.68M | -70.23M | -59.60M | -65.55M |
| Investing Cash Flow | -16.86M | -11.88M | -1.29M | -6.09M | -3.71M | -1.19M |
| Financing Cash Flow | 462.61M | 561.72M | 332.11M | 169.83M | 1.45M | 2.85M |
Ocular Therapeutix Technical Analysis
Positive
10.88
Price Trends
9.63
Positive
9.29
Positive
9.97
Positive
Market Momentum
0.52
Negative
60.62
Neutral
54.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OCUL, the sentiment is Positive. The current price of 10.88 is above the 20-day moving average (MA) of 9.87, above the 50-day MA of 9.63, and above the 200-day MA of 9.97, indicating a bullish trend. The MACD of 0.52 indicates Negative momentum. The RSI at 60.62 is Neutral, neither overbought nor oversold. The STOCH value of 54.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OCUL.
Ocular Therapeutix Risk Analysis
Ocular Therapeutix disclosed 54 risk factors in its most recent earnings report. Ocular Therapeutix reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ocular Therapeutix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $3.14B | -64.82 | -13.53% | ― | 105.17% | 53.58% | |
55 Neutral | $2.39B | -7.58 | -59.87% | ― | -8.14% | -10.60% | |
52 Neutral | $878.59M | -7.46 | -42.92% | ― | ― | 34.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $588.18M | -2.47 | -220.07% | ― | 12.00% | -9.21% | |
46 Neutral | $431.49M | -1.33 | -135.81% | ― | -94.63% | -39.78% | |
39 Underperform | $810.97M | -4.34 | -73.18% | ― | ― | 9.05% |
* Healthcare Sector Average
OCUL
Ocular Therapeutix
10.77
-1.75
-13.98%
EYPT
EyePoint Pharmaceuticals
4.99
-6.61
-56.98%
RGNX
RegenXBio
9.38
0.37
4.11%
TARS
Tarsus Pharmaceuticals
70.65
12.49
21.48%
OCS
Oculis Holding
12.97
-3.38
-20.67%
AURA
Aura Biosciences Inc
7.73
1.30
20.22%
Ocular Therapeutix Corporate Events
Executive/Board ChangesShareholder Meetings
Ocular Therapeutix Expands Equity Plan and Confirms Leadership
Positive
Jun 12, 2026
At its June 10, 2026 annual meeting, Ocular Therapeutix shareholders approved a significant expansion of the 2021 Stock Incentive Plan, authorizing an additional 10 million shares for equity awards. Shareholders also ratified PricewaterhouseCooper...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.